CNTA Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.46 |
| 52 Week High | US$18.97 |
| 52 Week Low | US$7.38 |
| Beta | 1.54 |
| 1 Month Change | -4.08% |
| 3 Month Change | 8.65% |
| 1 Year Change | 104.73% |
| 3 Year Change | 75.11% |
| 5 Year Change | n/a |
| Change since IPO | -24.32% |
Recent News & Updates
Are Investors Undervaluing Centessa Pharmaceuticals plc (NASDAQ:CNTA) By 30%?
Jan 02
Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring
Dec 31Recent updates
Are Investors Undervaluing Centessa Pharmaceuticals plc (NASDAQ:CNTA) By 30%?
Jan 02Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring
Dec 31Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?
Nov 14Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
Sep 25Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?
Aug 15Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high
Jun 14Shareholder Returns
| CNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.9% | 3.6% | 3.8% |
| 1Y | 104.7% | -6.1% | 24.4% |
Return vs Industry: CNTA exceeded the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: CNTA exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| CNTA volatility | |
|---|---|
| CNTA Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CNTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CNTA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 75 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
| CNTA fundamental statistics | |
|---|---|
| Market cap | US$2.00b |
| Earnings (TTM) | -US$161.26m |
| Revenue (TTM) | US$6.85m |
316.7x
P/S Ratio-13.5x
P/E RatioIs CNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTA income statement (TTM) | |
|---|---|
| Revenue | US$6.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.85m |
| Other Expenses | US$168.12m |
| Earnings | -US$161.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,353.20% |
| Debt/Equity Ratio | 15.2% |
How did CNTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 01:57 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Centessa Pharmaceuticals plc is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |